Format

Send to

Choose Destination
Am J Physiol Endocrinol Metab. 2015 Dec 15;309(12):E1008-18. doi: 10.1152/ajpendo.00345.2015. Epub 2015 Oct 20.

Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice.

Author information

1
Division of Gastroenterology, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio.
2
Division of Gastroenterology, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio michael.wolfe2@case.edu.

Abstract

Previous reports have suggested that the abrogation of gastric inhibitory polypeptide (GIP) signaling could be exploited to prevent and treat obesity and obesity-related disorders in humans. This study was designed to determine whether immunoneutralization of GIP, using a newly developed specific monoclonal antibody (mAb), would prevent the development of obesity. Specific mAb directed against the carboxy terminus of mouse GIP was identified, and its effects on the insulin response to oral and to intraperitoneal (ip) glucose and on weight gain were evaluated. Administration of mAb (30 mg/kg body wt, BW) to mice attenuated the insulin response to oral glucose by 70% and completely eliminated the response to ip glucose coadministered with human GIP. Nine-week-old C57BL/6 mice injected with GIP mAbs (60 mg·kg BW(-1)·wk(-1)) for 17 wk gained 46.5% less weight than control mice fed an identical high-fat diet (P < 0.001). No significant differences in the quantity of food consumed were detected between the two treatment groups. Furthermore, magnetic resonance imaging demonstrated that subcutaneous, omental, and hepatic fat were 1.97-, 3.46-, and 2.15-fold, respectively, lower in mAb-treated animals than in controls. Moreover, serum insulin, leptin, total cholesterol (TC), low-density lipoprotein (LDL), and triglycerides were significantly reduced, whereas the high-density lipoprotein (HDL)/TC ratio was 1.25-fold higher in treated animals than in controls. These studies support the hypothesis that a reduction in GIP signaling using a GIP-neutralizing mAb might provide a useful method for the treatment and prevention of obesity and related disorders.

KEYWORDS:

gastric inhibitory polypeptide; immunoneutralization; monoclonal antibody; obesity

PMID:
26487006
DOI:
10.1152/ajpendo.00345.2015
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center